Exosomes vs Stem Cells: What's the Difference

An exosome is not a stem cell. It is a lipid-bound particle roughly 30 to 150 nanometers wide, secreted by cells, carrying proteins, RNA, and other molecular cargo between cells [1]. A stem cell is a living, dividing cell. An exosome cannot divide, cannot become a new tissue, and cannot engraft anywhere. The American Society of Regional Anesthesia and Pain Medicine describes exosome products in regenerative medicine as "cell-free and hypo-immunogenic," meaning they carry little of the immune-rejection risk that comes with injecting living allogeneic cells [6]. Many exosome products marketed today are harvested from cultured mesenchymal stem cells (MSCs), so the marketing link between the two is not entirely invented, but the product itself contains no live cells [1][6].

The FDA does not treat that distinction as a safety pass. Its December 6, 2019 Public Safety Notification states plainly that "certain clinics across the country, including some that manufacture or market violative 'stem cell' products, are now also offering exosome products to patients," and that these clinics "deceive patients with unsubstantiated claims about the potential for these products to prevent, treat or cure various diseases or conditions" [2]. The same notice rejects the idea that exosomes sit outside drug law: "exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act and are subject to premarket review and approval requirements" [2]. As of that notice and still true today, there are zero FDA-approved exosome products [2][3]. A separate FDA consumer alert repeats the same line for both categories: stem cell products generally require FDA approval, and "as a general matter, exosome products intended to treat diseases or conditions in humans require FDA approval"; again, none currently have it [3].

Enforcement has followed the marketing. On December 30, 2024, the FDA sent a warning letter to Evolutionary Biologics, Inc. over five products sold as a single regenerative-medicine line: EXO RNA, an exosome product; EVO JEL, an umbilical-cord-derived product; EVO HYBRID, a cord-placenta-amniotic blend; EXO PERIO, marketed as "a Wharton's Jelly product rich with Mesenchymal Stem Cell exosomes"; and EXO RX, marketed to repair tissue and reduce inflammation. The FDA classified every one of them as an unapproved drug and biological product requiring a Biologics License Application the company did not have [4]. That single letter shows the pattern industry-wide: exosome, cord-tissue, and stem cell claims get bundled into one sales pitch even though only one of those product types (cord-blood-derived hematopoietic stem cells for blood disorders) has any FDA approval at all [3][4].

The clinical harm record for exosomes is smaller than for stem cells but already documented. A October 2025 case series in the Journal of Cosmetic Dermatology by Kui Young Park reported four adult women who received intradermal exosome injections at non-dermatology clinics or beauty salons, none under medical supervision [5]. All four developed persistent erythema, nodules, or granulomatous inflammation; treatments included systemic corticosteroids, intralesional steroids, laser therapy, and surgical removal; every patient was left with residual scarring and incomplete resolution [5]. The same paper cites a separate case of skin necrosis following a lyophilized exosome injection, confirmed on histopathology as granulomatous inflammation with necrotic vascular changes, and a case of multiple foreign-body granulomas after dermal injection of umbilical-cord-blood MSC-conditioned media [5]. Park's paper states the underlying regulatory gap directly: "although approved for topical use, intradermal injection of these cosmetic products remains off-label and unregulated in many countries, including South Korea" [5]. The same gap exists in the United States, where the FDA's own reporting page for adverse events groups stem cells, exosomes, and other regenerative products together because patients keep getting hurt by all three under the same marketing umbrella [7].

For a longevity-minded reader the practical read is this: exosome injections are not a gentler, cell-free version of stem cell therapy that sidesteps the regulatory problem. They sidestep nothing. No exosome product has cleared FDA or EMA review for any indication, the same enforcement letters that target stem cell clinics now list exosome products on the same page, and the documented harms (scarring, granulomas, necrosis) come from formulations with no disclosed manufacturer, dose, or purity data [2][4][5]. Ask any clinic offering exosomes the same three questions used for stem cell offers: is this under an active FDA-cleared investigational new drug application, can you name the manufacturer and lot number, and will you put the answer in writing.